LABStandard BioTools Inc.

$388M

Q3 2023 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$25M-1.1% YoY

Gross Profit

$11M44.0% margin

Operating Income

-$21M-83.5% margin

Net Income

-$21M-82.8% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

-8.3%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$12M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$339M

Total Liabilities

$471M

Stockholders' Equity

-$132M

Cash & Equivalents

$80M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$26M	-1.1%
Gross Profit	$11M	$9M	+21.0%
Operating Income	-$21M	-$29M	+27.1%
Net Income	-$21M	-$29M	+28.6%

Revenue Segments

Product And Service

$25M36%

Product

$19M27%

Consumables

$10M14%

Instruments

$9M13%

Service

$7M9%

Product and Service, Other

$90,0000%

Geographic Segments

Americas

$11M43%

EMEA

$8M32%

Asia Pacific

$6M25%

LAB Q3 2023 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena